Literature DB >> 2981728

Anatomy of the corticotropin-releasing factor and opiomelanocortin systems of the brain.

S A Joseph, W H Pilcher, K M Knigge.   

Abstract

Using antiserums generated against the neuropeptides corticotropin-releasing factor (CRF), beta-endorphin, and adrenocorticotropin, we have immunocytochemically mapped the organization of these hormones throughout the brain. The distribution of CRF perikarya is widespread throughout the forebrain, brain stem, and spinal cord. The central opiomelanocortin system is represented by two separate pools of neuronal perikarya: the hypothalamic arcuate pool, and the medullary (nucleus tractus solitarius) pool. From these groups fibers distribute widely throughout forebrain and brain stem. A conspicuous codistribution pattern exists between the CRF perikarya and opiomelanocortin fibers. Analysis of these systems within the brain stem and spinal cord reveals innervation and distribution patterns within regions containing catecholamine systems, areas associated with regulation of sympathetic and parasympathetic outflow, cardiovascular and respiratory homeostatic centers, and regions associated with stress, autonomic homeostasis, and pain modulation. By virtue of these extensive brain-stem distributions, it is suggested that an anatomical substrate exists for participation of these peptide systems in the integration of certain autonomic, visceral, and homeostatic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981728

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  11 in total

Review 1.  The vagus nerve, food intake and obesity.

Authors:  Hans-Rudolf Berthoud
Journal:  Regul Pept       Date:  2008-03-25

2.  Cholecystokinin octapeptide increases spontaneous glutamatergic synaptic transmission to neurons of the nucleus tractus solitarius centralis.

Authors:  V Baptista; Z L Zheng; F H Coleman; R C Rogers; R A Travagli
Journal:  J Neurophysiol       Date:  2005-08-10       Impact factor: 2.714

3.  Central vagal afferent endings mediate reduction of food intake by melanocortin-3/4 receptor agonist.

Authors:  Carlos A Campos; Hiroko Shiina; Robert C Ritter
Journal:  J Neurosci       Date:  2014-09-17       Impact factor: 6.167

4.  Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression.

Authors:  K L Brunson; N Khan; M Eghbal-Ahmadi; T Z Baram
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

5.  Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones.

Authors:  S J Li; K Varga; P Archer; V J Hruby; S D Sharma; R A Kesterson; R D Cone; G Kunos
Journal:  J Neurosci       Date:  1996-08-15       Impact factor: 6.167

Review 6.  ACTH treatment of infantile spasms: mechanisms of its effects in modulation of neuronal excitability.

Authors:  K L Brunson; S Avishai-Eliner; T Z Baram
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

Review 7.  How do the many etiologies of West syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis.

Authors:  K L Brunson; M Eghbal-Ahmadi; T Z Baram
Journal:  Brain Dev       Date:  2001-11       Impact factor: 1.961

Review 8.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

9.  Presynaptic melanocortin-4 receptors on vagal afferent fibers modulate the excitability of rat nucleus tractus solitarius neurons.

Authors:  Shuxia Wan; Kirsteen N Browning; F Holly Coleman; Gregory Sutton; Hiyuan Zheng; Andrew Butler; Hans-Rudolf Berthoud; R Alberto Travagli
Journal:  J Neurosci       Date:  2008-05-07       Impact factor: 6.167

10.  Volume transmission of beta-endorphin via the cerebrospinal fluid; a review.

Authors:  Jan G Veening; Peter O Gerrits; Henk P Barendregt
Journal:  Fluids Barriers CNS       Date:  2012-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.